CN109475538A - 使用异丁司特治疗酗酒和抑郁和/或焦虑情绪 - Google Patents

使用异丁司特治疗酗酒和抑郁和/或焦虑情绪 Download PDF

Info

Publication number
CN109475538A
CN109475538A CN201780039546.XA CN201780039546A CN109475538A CN 109475538 A CN109475538 A CN 109475538A CN 201780039546 A CN201780039546 A CN 201780039546A CN 109475538 A CN109475538 A CN 109475538A
Authority
CN
China
Prior art keywords
ibudilast
alcohol
patient
aud
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780039546.XA
Other languages
English (en)
Chinese (zh)
Inventor
岩城裕
岩城裕一
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicinova Inc
Original Assignee
Medicinova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicinova Inc filed Critical Medicinova Inc
Publication of CN109475538A publication Critical patent/CN109475538A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780039546.XA 2016-05-10 2017-05-09 使用异丁司特治疗酗酒和抑郁和/或焦虑情绪 Pending CN109475538A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662333990P 2016-05-10 2016-05-10
US62/333,990 2016-05-10
PCT/US2017/031775 WO2017196857A1 (en) 2016-05-10 2017-05-09 Treatment of alcoholism and depression and/or dysphoric mood using ibudilast

Publications (1)

Publication Number Publication Date
CN109475538A true CN109475538A (zh) 2019-03-15

Family

ID=60267401

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780039546.XA Pending CN109475538A (zh) 2016-05-10 2017-05-09 使用异丁司特治疗酗酒和抑郁和/或焦虑情绪

Country Status (7)

Country Link
US (1) US20190151294A1 (cg-RX-API-DMAC10.html)
EP (1) EP3454853B1 (cg-RX-API-DMAC10.html)
JP (1) JP2019514978A (cg-RX-API-DMAC10.html)
CN (1) CN109475538A (cg-RX-API-DMAC10.html)
CA (1) CA3023439A1 (cg-RX-API-DMAC10.html)
ES (1) ES2917618T3 (cg-RX-API-DMAC10.html)
WO (1) WO2017196857A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114514024A (zh) * 2019-09-05 2022-05-17 Healx有限公司 用异丁司特与二甲双胍、大麻二酚、舍曲林或槲皮素的组合对脆性x综合征的治疗

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070072899A1 (en) * 2005-09-26 2007-03-29 Johnson Kirk W Method for treating drug and behavioral addictions
US20080167291A1 (en) * 2006-05-09 2008-07-10 Braincells, Inc. Neurogenesis by modulating angiotensin
CN101309682A (zh) * 2005-10-21 2008-11-19 脑细胞股份有限公司 通过pde抑制调节神经发生
US20090028816A1 (en) * 2007-07-27 2009-01-29 Lance Sultzbaugh Treatment of depression, psychosis, and anxiety
CN101848712A (zh) * 2007-07-11 2010-09-29 美迪诺亚公司 用异丁地特治疗渐进性神经变性疾病
US20150051191A1 (en) * 2013-08-15 2015-02-19 Medicinova, Inc. Treatment of alcoholism using ibudilast

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007047978A2 (en) * 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070072899A1 (en) * 2005-09-26 2007-03-29 Johnson Kirk W Method for treating drug and behavioral addictions
CN101309682A (zh) * 2005-10-21 2008-11-19 脑细胞股份有限公司 通过pde抑制调节神经发生
US20080167291A1 (en) * 2006-05-09 2008-07-10 Braincells, Inc. Neurogenesis by modulating angiotensin
CN101848712A (zh) * 2007-07-11 2010-09-29 美迪诺亚公司 用异丁地特治疗渐进性神经变性疾病
US20090028816A1 (en) * 2007-07-27 2009-01-29 Lance Sultzbaugh Treatment of depression, psychosis, and anxiety
US20150051191A1 (en) * 2013-08-15 2015-02-19 Medicinova, Inc. Treatment of alcoholism using ibudilast

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARYW. KURIA: "The Association between Alcohol Dependence and Depression before and after Treatment for Alcohol Dependence", 《ISRN PSYCHIATRY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114514024A (zh) * 2019-09-05 2022-05-17 Healx有限公司 用异丁司特与二甲双胍、大麻二酚、舍曲林或槲皮素的组合对脆性x综合征的治疗

Also Published As

Publication number Publication date
CA3023439A1 (en) 2017-11-16
EP3454853B1 (en) 2022-05-18
ES2917618T3 (es) 2022-07-11
WO2017196857A1 (en) 2017-11-16
JP2019514978A (ja) 2019-06-06
EP3454853A1 (en) 2019-03-20
EP3454853A4 (en) 2020-01-15
US20190151294A1 (en) 2019-05-23

Similar Documents

Publication Publication Date Title
JP5289765B2 (ja) 自閉症、強迫神経症、および衝動性の治療のためのメマンチン（ナメンダ）の使用
Vonghia et al. Acute alcohol intoxication
Katz et al. The history of acetylcholinesterase inhibitors in the treatment of myasthenia gravis
Preston et al. Effects of cocaine alone and in combination with mazindol in human cocaine abusers.
JP2025510913A (ja) 双極性障害の処置のための５－ＭｅＯ－ＤＭＴ
Zhang et al. Postoperative anticholinergic poisoning: concealed complications of a commonly used medication
US20150051191A1 (en) Treatment of alcoholism using ibudilast
JPH09323927A (ja) 慢性閉塞性動脈硬化症の治療のためのカルニチン誘導体含有薬剤
JPH0227327B2 (cg-RX-API-DMAC10.html)
Ballenger Unrecognized prevalence of panic disorder in primary care, internal medicine and cardiology
JP4276779B2 (ja) 注意欠損／活動亢進症の治療のためのアルカノイルカルニチン誘導体の使用
Wenzel et al. Central-nervous side effects of midazolam during transesophageal echocardiography
ES2917618T3 (es) Tratamiento del alcoholismo y la depresión mediante el uso de ibudilast
CN120813353A (zh) 用于治疗勃起功能障碍的化合物
Gorman Panic disorders
Fann et al. Effect of antidepressant and antimanic drugs on amine uptake in man
Akgun et al. Central nervous system stimulants and drugs that suppress appetite
JP5109132B2 (ja) 注意欠陥・多動性障害の治療薬
Gelenberg et al. Bipolar disorder
CN107115332A (zh) 一种用于治疗运动神经元病的组合物及其用途
WO2021023675A1 (en) Lacosamide for the treatment of add/adhd
JP2026501897A (ja) 単回有効非経口用量の短時間作用型サイケデリック剤の非経口投与による精神障害または神経障害の治療
WO2025145241A1 (en) Treatment of gut-brain interaction disorders
Kashyap et al. A Textbook Of Modern Pharmacology And Toxicology
Anderson et al. Safety of Atomoxetine in Combination with Intravenous Cocaine in Cocaine-Experienced Participants

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190315

WD01 Invention patent application deemed withdrawn after publication